No Data
zhongtai: In Q3 2024, traditional chinese medicine companies are experiencing temporary pressure, while end demand has slightly rebounded.
In the third quarter of 2024, traditional chinese medicine companies are experiencing temporary performance pressure, but gross margin is expected to improve upward from 2025.
Beijing Tongrentang (600085.SH): Currently not carrying out traditional Chinese medicine siasun robot&automation projects.
Gelonghui Nov 8th ǀ Beijing Tongrentang (600085.SH) stated on the interactive platform that the company's main business is the production and sales of Chinese patent medicine, and it is currently not engaged in traditional Chinese medicine siasun robot&automation projects.
Deng Xiaofeng newly invested in a resource stock.
Private equity tycoons Feng Liu and Deng Xiaofeng's latest holdings are here! In the third quarter, Feng Liu's managed Gaoyi Linshan No. 1 Yuanwang Fund entered the top ten list of tradable shareholders of 10 A-share companies, with a total market cap of approximately 19.538 billion yuan. Specifically, in the third quarter, Feng Liu increased his holdings in Beijing Tongrentang, Yantai Dongcheng Biochemicals, and Jonjee Hi-Tech Industrial and Commercial Holding; reduced his holdings in Angel Yeast Co., Ltd. and Nanjing King-Friend Biochemical Pharmaceutical; maintained his position unchanged in Hangzhou Hikvision Digital Technology, LB Group Co., Ltd., Shengyi Technology, Xinxiang Richful Lube Additive, and Shanghai Titan Scientific Co., Ltd. Deng Xiaofeng's managed Gaoyi Xiaofeng No. 2 Fund entered the top ten list of tradable shareholders of 13 A-share companies in the third quarter, with a total market cap of approximately 7.917 billion yuan. Gaoyi Xiaofeng Hongyuan Fund
Private Equity tycoons Feng Liu and Deng Xiaofeng's latest heavy-holdings stocks are here!
Deng Xiaofeng is reducing holdings
Zheshang: Innovative drugs and blood products sectors may benefit from slow demand recovery on the demand side.
Zheshang has released research reports stating that the transition of old and new dynamics in the pharmaceutical industry will continue in the future. Areas with innovative drugs, supply-side structural reform, or a good layout (innovative drugs supporting industry chain, large infusion solutions, potent anaesthetics, blood products, pharmaceutical circulation, traditional Chinese medicine OTC) could benefit from the slow recovery on the demand side, potentially showing better growth prospects.
beijing tongrentang (600085.SH): Obtained Canadian product license
Gelonghui, October 31st | Beijing Tongrentang (600085.SH) announced that its subsidiary Beijing Tongrentang Co., Ltd. Tongrentang Pharmaceutical Factory (referred to as Tongrentang Pharmaceutical Factory) has received the 'Product License (Class III)' approved by the Canadian Department of Health, and Tongrentang Pharmaceutical Factory's product Yangyin Qingfei Pills has obtained product registration in Canada.
No Data
No Data